{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:40:07Z","timestamp":1791906007105,"version":"4.3.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.cardfail.2015.10.022","type":"journal-article","created":{"date-parts":[[2015,11,10]],"date-time":"2015-11-10T22:30:31Z","timestamp":1447194631000},"page":"256-262","source":"Crossref","is-referenced-by-count":51,"title":["Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure"],"prefix":"10.1016","volume":"22","author":[{"given":"Benjamin","family":"French","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Ky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Brandimarto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupam","family":"Basuray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy K.","family":"Sweitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Cappola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2015.10.022_bib0010","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1161\/CIR.0000000000000152","article-title":"Heart disease and stroke statistics\u20142015 update: a report from the American Heart Association","volume":"131","author":"Mozaffarian","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2015.10.022_bib0015","doi-asserted-by":"crossref","first-page":"III-6","DOI":"10.1002\/clc.4960231503","article-title":"The economic burden of heart failure","volume":"23","author":"O'Connell","year":"2000","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.cardfail.2015.10.022_bib0020","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1161\/01.CIR.0000145158.33801.F3","article-title":"Ongoing myocardial injury in stable severe heart failure: value of cardiac troponin T monitoring for high-risk patient identification","volume":"110","author":"Perna","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2015.10.022_bib0025","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.jacc.2012.12.044","article-title":"B-Type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction","volume":"61","author":"van Veldhuisen","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2015.10.022_bib0030","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCHEARTFAILURE.110.958223","article-title":"High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure","volume":"4","author":"Ky","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2015.10.022_bib0035","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1023\/B:GLYC.0000014082.99675.2f","article-title":"Extracellular functions of galectin-3","volume":"19","author":"Ochieng","year":"2004","journal-title":"Glycoconj J"},{"key":"10.1016\/j.cardfail.2015.10.022_bib0040","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.bbagen.2005.12.020","article-title":"Galectin-3: an open-ended story","volume":"1760","author":"Dumic","year":"2006","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.cardfail.2015.10.022_bib0045","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1073\/pnas.0511167103","article-title":"Galectin-3 regulates myofibroblast activation and hepatic fibrosis","volume":"103","author":"Henderson","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cardfail.2015.10.022_bib0050","doi-asserted-by":"crossref","first-page":"H404","DOI":"10.1152\/ajpheart.00747.2008","article-title":"N-Acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion\/growth-regulatory lectin","volume":"296","author":"Liu","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.cardfail.2015.10.022_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11897-010-0004-x","article-title":"Galectin-3 in cardiac remodeling and heart failure","volume":"7","author":"de Boer","year":"2010","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.cardfail.2015.10.022_bib0060","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1161\/01.CIR.0000147181.65298.4D","article-title":"Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction","volume":"110","author":"Sharma","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2015.10.022_bib0065","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/CRD.0000000000000013","article-title":"Comprehensive review of the prognostic value of galectin-3 in heart failure","volume":"22","author":"Coburn","year":"2014","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.cardfail.2015.10.022_bib0070","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.amjcard.2011.03.056","article-title":"Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival","volume":"108","author":"Tang","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2015.10.022_bib0075","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ijcard.2011.05.081","article-title":"Galectin-3 in heart failure: high levels are associated with all-cause mortality","volume":"150","author":"Ueland","year":"2011","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cardfail.2015.10.022_bib0080","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/eurjhf\/hfr151","article-title":"Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial","volume":"14","author":"Lopez-Andr\u00e8s","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2015.10.022_bib0085","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00392-010-0125-y","article-title":"Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the Deal-HF study","volume":"99","author":"Lok","year":"2010","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.cardfail.2015.10.022_bib0090","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1161\/CIRCHEARTFAILURE.111.963637","article-title":"Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study","volume":"5","author":"Felker","year":"2012","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2015.10.022_bib0095","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijcard.2013.08.081","article-title":"Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction","volume":"169","author":"Carrasco-S\u00e1nchez","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cardfail.2015.10.022_bib0100","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jchf.2013.12.004","article-title":"Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure","volume":"2","author":"Ahmad","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2015.10.022_bib0105","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jacc.2013.07.087","article-title":"Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3","volume":"63","author":"Bayes-Genis","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2015.10.022_bib0110","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/07853890.2010.538080","article-title":"Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction","volume":"43","author":"de Boer","year":"2011","journal-title":"Ann Med"},{"key":"10.1016\/j.cardfail.2015.10.022_bib0115","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1161\/CIRCULATIONAHA.113.006855","article-title":"Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes","volume":"129","author":"Basuray","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2015.10.022_bib0120","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1515\/cclm-2013-0942","article-title":"Analytical evaluation of the automated galectin-3 assay on the Abbott Architect immunoassay instruments","volume":"52","author":"Gaze","year":"2014","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.cardfail.2015.10.022_bib0125","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1161\/CIRCHEARTFAILURE.111.965020","article-title":"Multiple biomarkers for risk prediction in chronic heart failure","volume":"5","author":"Ky","year":"2012","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2015.10.022_bib0130","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.0006-341X.2000.00337.x","article-title":"Time-dependent ROC curves for censored survival data and a diagnostic marker","volume":"56","author":"Heagerty","year":"2000","journal-title":"Biometrics"},{"key":"10.1016\/j.cardfail.2015.10.022_bib0135","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2012.04.053","article-title":"Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community","volume":"60","author":"Ho","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2015.10.022_bib0140","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/ejhf.203","article-title":"Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial","volume":"17","author":"Edelmann","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2015.10.022_bib0145","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","article-title":"Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction","volume":"2","author":"Mohammed","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2015.10.022_bib0150","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1161\/01.CIR.0000054164.99881.00","article-title":"Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT)","volume":"107","author":"Anand","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2015.10.022_bib0155","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.jacc.2009.07.025","article-title":"Profiles of serial changes in cardiac troponin T concentrations and outcome in ambulatory patients with chronic heart failure","volume":"54","author":"Miller","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2015.10.022_bib0160","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1161\/CIRCULATIONAHA.114.012243","article-title":"Letter by Psaty et al regarding article, \u201cHeart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes\u201d","volume":"131","author":"Psaty","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2015.10.022_bib0165","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1161\/CIRCULATIONAHA.114.012888","article-title":"Response to letter regarding article, \u201cHeart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes","volume":"131","author":"Basuray","year":"2015","journal-title":"Circulation"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107191641501177X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107191641501177X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T20:55:05Z","timestamp":1537217705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107191641501177X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S107191641501177X"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2015.10.022","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}